TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

NCT05901428 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1736

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

Fudan University